Category Archives: TCR

TCR2 Tx Pivots Away from Liquid Tumors; Will Enhanced TRuC-Ts Improve Efficacy in Solid Tumors? TCR2 Tx Explores New Targets and Allogeneic Candidates; TCR2 Tx’s R&D Day

On Wednesday, October 20, TCR2 Therapeutics held an R&D Day (press release / presentation) highlighting the reprioritization of their pipeline to solely focus on solid tumors. Additionally, management reported updated safety data from gavo-cel’s (TC-210; mesothelin TRuC-T) Ph1/2 trial and additional details on the design of the Ph2 portion. TCR2 Tx presented their strategy for TRuC-T enhancements, new targets in development, and their allogeneic program. Finally, on Tuesday, October 19, a change in TCR2 Tx’s website and logo was observed.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

T-Cure Partners With Atlas to Develop a KK-LC-1 Diagnostic Test

On Tuesday, October 5, T-Cure announced (press release) a collaborative agreement with Atlas Antibodies for the development, manufacture, and supply of CT83 (KK-LC-1-directed monoclonal antibody). Of note, CT83 will be used for the development of a diagnostic test to identify KK-LC-1-expressing tumors. Below, Celltelligence provides insights on how the use of a companion diagnostic test could improve clinical outcomes, while discussing T-Cure’s novel TCR-T pipeline.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Ziopharm’s TCR-T Program Pushed Back to H1 2022; Ziopharm Sheds Over 50% of Its Workforce

On Monday, September 27, Ziopharm announced (press release) that they have reduced their staffing levels by over 50% (eliminating 60 positions) while extending their cash runway into H1 2023. Additionally, management confirmed that the first patient from the Ph1/2 TCR-T Library trial is expected to be dosed in H1 2022. Below, Celltelligence provides insights on Ziopharm’s TCR-T program delay, in-house manufacturing strategy, and if the company’s latest measures will regain shareholders’ confidence.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

TCR2 on Track to Identify Gavo-cel’s (Mesothelin TRuC-T) RP2D by YE 2021; Will Checkpoint Inhibitors Improve Gavo-cel’s Efficacy? ESMO 2021 Day 2

On Friday, September 17, TCR2 Tx held an investor call (press release / presentation) highlighting updated clinical data presented at ESMO from gavo-cel’s (TC-210; autologous mesothelin TRuC-T) Ph1/2 trial in advanced mesothelin-expressing cancers. Below, Celltelligence provides insights on TCR2’s approach to find gavo-cel’s RP2D, and how combining a PD1 inhibitor with gavo-cel could improve the TRuC-T’s efficacy profile, while discussing gavo-cel’s potential expansion into other indications.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

GSK Explores Better Patient Selection Methods for Lete-cel; Could 2seventy bio Nominate Medigene’s PRAME TCR-T as Their Second Target? Adaptimmune Presents Preclinical Data from ADP-A2M4CD8; No Updated Preclinical Results from Carisma; Tecartus Absent from CHMP Highlights; ESMO 2021 Day 1&2

On the first two days of ESMO 2021, four key pre-clinical and clinical presentations from GSK, Medigene, Adaptimmune, and Carisma were presented. On Friday, September 17, the CHMP highlights for September were released. Of note, no updates from Tecartus’s Type II variation for r/r adult ALL were observed. Below, Celltelligence provides insights and context for each presentation, while providing likely EU approval timelines for Tecartus.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Adaptimmune’s ADP-A2M4CD8 Has a Best Response With Ovarian Cancer Patients; Legend’s LB1901 Ph1 Trial Initiated in the US

On Monday, September 13, Adaptimmune reported (press release / presentation) updated data from ADP-A2M4CD8’s (MAGE-A4 SPEAR-T) Ph1 SURPASS study for multiple solid tumors. Of note, Adaptimmune highlighted ADP-A2M4CD8’s safety profile and compared initial efficacy data to the company’s first-generation MAGE-A4 SPEAR-T therapy (afami-cel; formerly ADP-A2M4). On the same day, Legend announced (press release) the start of LB1901’s (CD4 CAR-T) Ph1 trial in the US for r/r peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). Below, Celltelligence provides insights on which indications Adaptimmune could prioritize, while discussing Legend’s clinical development of LB1901 in the TCL setting.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Adaptimmune’s Novel Gene Editing Approach; Do iPSC-derived αβT Cells Have an Advantage Over NK Cells? Thoughts on Adaptimmune’s Allogeneic Platform Virtual Event 2021

On Thursday, September 9, Adaptimmune held a virtual event (presentation) discussing the scope of their recent Genentech (Roche) collaboration. Additionally, management highlighted Adaptimmune’s strategy to knockout recombination-activating gene (RAG) in order to eliminate native TCR expression, while announcing the completion of a new allogeneic manufacturing facility by YE 2022 in Milton Park, UK. Below, Celltelligence provides insights on how Adaptimmune’s collaboration with Genentech (Roche) could potentially impact GSK’s TCR-T strategy, Adaptimmune’s decision to develop iPSC-derived αβT cells, and which alternative lymphodepletion regimens could be used for their allogeneic products.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Adaptimmune Discusses Novel Engineering and Lymphodepleting Regimens During Their Allogeneic Platform Virtual Event 2021

On Thursday, September 9, Adaptimmune held a virtual event discussing their allogeneic platform (presentation). Although no significant updates were provided relating to the Genentech partnership, management discussed the overall scope and financial terms of the deal over two slides (see below).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Adaptimmune Partners With Genentech to Develop iPSC-derived Allogeneic TCR-Ts

On Tuesday, September 7, Adaptimmune announced (press release) a strategic collaboration and license agreement with Genentech (Roche) to develop and commercialize allogeneic T cell therapies for multiple oncology indications. Of note, Adaptimmune will receive $150M upfront and further milestone payments potentially exceeding $3B in aggregate value. Below, Celltelligence provides insights on how Genentech (Roche) could leverage their extensive capabilities to quickly advance allogeneic TCR-Ts into the clinic, while discussing Adaptimmune’s strategy to become a leader in the allogeneic TCR-T space.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Precision Partners With Tiziana for the Use of Foralumab as a Novel Lymphodepletion Agent; How Could an Anti-CD3 Antibody Improve CAR-T Efficacy? TCR2 Tx’s Gavo-cel Receives Orphan Drug Designation

On Thursday, September 2, Precision BioSciences announced (press release) an exclusive license agreement with Tiziana to evaluate foralumab (anti-CD3 monoclonal antibody) as a lymphodepletion (LD) agent for their allogeneic CAR-T therapies. On the same day, TCR2 Tx reported (press release) that the FDA has granted gavo-cel (mesothelin-targeted TRuC-T) Orphan Drug Designation (ODD) for the treatment of cholangiocarcinoma. Below, Celltelligence provides insights on how a foralumab LD regimen could enhance allogeneic CAR-T efficacy, while discussing gavo-cel’s ODD in cholangiocarcinoma.  

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.